パーソナライズド新生児療法:治療上の孤児集団におけるマジストラル・フォーミュラの適用
Wenwen Shao1, Angela Gomez2, Alejandra Alejano1
1Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, 28922 Alcorcón, Spain.
Pharmaceutics
|August 28, 2025
まとめ
マジストラル・フォーミュラ (MF) は,承認された治療法がない新生児に潜在的な解決策を提供します. このレビューは,小児薬の開発における課題と,より良く配列された,証拠に基づいた新生児医薬品の必要性を強調しています.
科学分野:
- 新生児薬理学
- 小児薬剤
- 根拠に基づいた医療
背景:
- 新生児に対する承認された治療法の利用可能性は限られている.
- 新生児と成人の生理学的違いは 薬剤の配列を複雑にします
- 小児科の研究の課題は 臨床試験の少ないことと 処方箋外薬の使用です
研究 の 目的:
- 新生児に対する治療の選択肢として マジストラル・フォーミュラ (MF) を検討する.
- 新生児のMFに対する薬剤形態,徴候,および用量勧告を分析する.
- 承認された新生児の薬の不足に対処するために
主な方法:
- 新生児用医薬品に関する科学文献のレビュー
- 小児科,特に新生児に対して一般的に使用されるマジストラル・フォーミュラの分析.
- 治療用グループによる薬物の分類 (抗高血圧薬,コルチコステロイド,抗薬).
主要な成果:
- 新生児は新生児集中治療室や初等保健医療で 処方箋外薬を投与されることが多いです
- マジストラル製薬は小児用薬として製薬される.
- 新生児と成人の間で有意な薬理学的な違いがある.
結論:
- 新生児向けの小児薬の設計に関する研究と開発を推進することが不可欠です.
- 年齢に適した用量形態と改善された薬物情報が必要である.
- 承認された新生児用医薬品の不足に対処するには 拡大した研究と規制上の支援が必要です
関連する概念動画
01:02Prescription, Nonprescription and Orphan Drugs
1.5K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.5K
01:24Dosage Regimen: Individualization
388
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
388
01:29Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
960
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
960
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
552
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
552
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
404
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
404